Published in Muscle Nerve on September 01, 2007
Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron (2012) 1.78
Retrospective study on PET-SPECT imaging in a large cohort of myotonic dystrophy type 1 patients. Neurol Sci (2010) 1.58
The brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease. Brain (2011) 1.36
Myotonic dystrophy. Neurol Clin (2014) 1.08
Therapeutics development in myotonic dystrophy type 1. Muscle Nerve (2011) 1.07
Myotonic dystrophy mouse models: towards rational therapy development. Trends Mol Med (2011) 1.07
Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol (2010) 1.07
Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain. PLoS One (2012) 1.05
Pathogenic RNAs in microsatellite expansion disease. Neurosci Lett (2009) 1.01
Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol (2013) 1.01
CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease. Mol Cell Neurosci (2012) 0.98
White matter abnormalities and neurocognitive correlates in children and adolescents with myotonic dystrophy type 1: a diffusion tensor imaging study. Neuromuscul Disord (2010) 0.96
Diffusion tensor imaging reveals widespread white matter abnormalities in children and adolescents with myotonic dystrophy type 1. J Neurol (2012) 0.94
Neuropathology does not Correlate with Regional Differences in the Extent of Expansion of CTG Repeats in the Brain with Myotonic Dystrophy Type 1. Acta Histochem Cytochem (2010) 0.94
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
High disease impact of myotonic dystrophy type 2 on physical and mental functioning. J Neurol (2011) 0.90
Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol (2012) 0.88
Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study. J Neurol (2008) 0.87
Cognitive impairment in myotonic dystrophy type 1 is associated with white matter damage. PLoS One (2014) 0.85
Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain (2013) 0.84
Depression in Myotonic Dystrophy type 1: clinical and neuronal correlates. Behav Brain Funct (2010) 0.83
Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2. J Neurol (2008) 0.83
Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1. J Neurol Sci (2014) 0.82
Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2. J Neurol (2014) 0.81
Prevalence and correlates of apathy in myotonic dystrophy type 1. BMC Neurol (2015) 0.79
How genetics affects the brain to produce higher-level dysfunctions in myotonic dystrophy type 1. Funct Neurol (2015) 0.79
Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing. Rare Dis (2013) 0.79
Myotonic dystrophies as a brain disorder. Neurol Sci (2010) 0.78
Validation of sensitivity and specificity of tetraplet-primed PCR (TP-PCR) in the molecular diagnosis of myotonic dystrophy type 2 (DM2). J Mol Diagn (2010) 0.78
In myotonic dystrophy type 1 reduced FDG-uptake on FDG-PET is most severe in Brodmann area 8. BMC Neurol (2016) 0.76
Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study. Orphanet J Rare Dis (2016) 0.76
Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. Neurol Sci (2016) 0.76
Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). Neurology (2015) 0.76
Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1. Neuroimage Clin (2016) 0.76
Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies. J Neurodegener Dis (2013) 0.75
Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism. J Neuromuscul Dis (2015) 0.75
Congenital myotonic dystrophy: ventriculomegaly and shunt considerations for the pediatric neurosurgeon. Childs Nerv Syst (2016) 0.75
Cortical Thickness and White Matter Integrity are Associated with CTG Expansion Size in Myotonic Dystrophy Type I. Yonsei Med J (2017) 0.75
Myotonic Dystrophies: State of the Art of New Therapeutic Developments for the CNS. Front Cell Neurosci (2017) 0.75
Myotonic dystrophy-1 complicated by factor-v (leiden) mutation. Case Rep Med (2015) 0.75
Myotonic dystrophy type 1 associated with white matter hyperintense lesions: clinic, imaging, and genetic analysis. Chin Med J (Engl) (2015) 0.75
Brain Connectomics' Modification to Clarify Motor and Nonmotor Features of Myotonic Dystrophy Type 1. Neural Plast (2016) 0.75
Assessment of Premutation in Myotonic Dystrophy Type 1 Affected Family Members by TP-PCR and Genetic Counseling. Case Rep Med (2014) 0.75
Dystrophia myotonica type 1 presenting with dysarthria: A case report and literature review. Exp Ther Med (2017) 0.75
Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest (2002) 2.48
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Increased visceral adipose tissue rather than BMI as a risk factor for dementia. Age Ageing (2007) 0.91
Parkinsonism and essential tremor in a family with pseudo-dominant inheritance of PARK2: an FP-CIT SPECT study. Mov Disord (2007) 0.88
Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism. Ann Neurol (2004) 0.85
Myotonia congenita: novel mutations in CLCN1 gene and functional characterizations in Italian patients. J Neurol Sci (2012) 0.84
Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments. Biomed Res Int (2013) 0.83
Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. Eur J Nucl Med Mol Imaging (2008) 0.81
Relation between wall thickening on gated perfusion SPECT and functional recovery after coronary revascularization in patients with previous myocardial infarction. Eur J Nucl Med Mol Imaging (2004) 0.80
Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol (2012) 0.80
Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17. Mov Disord (2006) 0.80
Meditation training for people with amyotrophic lateral sclerosis and their caregivers. J Altern Complement Med (2013) 0.80
Nigrostriatal involvement in ataxia with oculomotor apraxia type 1. J Neurol (2007) 0.78
NOTCH3 gene mutations in subjects clinically suspected of CADASIL. J Neurol Sci (2011) 0.78
SPECT imaging of GABA(A)/benzodiazepine receptors and cerebral perfusion in mild cognitive impairment. Eur J Nucl Med Mol Imaging (2010) 0.78
Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging (2007) 0.77